Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5088656
Max Phase: Preclinical
Molecular Formula: C47H54N10O6
Molecular Weight: 855.01
Molecule Type: Unknown
Associated Items:
ID: ALA5088656
Max Phase: Preclinical
Molecular Formula: C47H54N10O6
Molecular Weight: 855.01
Molecule Type: Unknown
Associated Items:
Canonical SMILES: Nc1nnc(-c2ccccc2O)cc1N1CC2CCC(C1)N2c1cccc(OCCN2CCN(CC3CCN(c4ccc5c(c4)C(=O)N(C4CCC(=O)NC4=O)C5=O)CC3)CC2)c1
Standard InChI: InChI=1S/C47H54N10O6/c48-44-41(26-39(50-51-44)37-6-1-2-7-42(37)58)55-28-33-8-9-34(29-55)56(33)32-4-3-5-35(24-32)63-23-22-52-18-20-53(21-19-52)27-30-14-16-54(17-15-30)31-10-11-36-38(25-31)47(62)57(46(36)61)40-12-13-43(59)49-45(40)60/h1-7,10-11,24-26,30,33-34,40,58H,8-9,12-23,27-29H2,(H2,48,51)(H,49,59,60)
Standard InChI Key: NZXFUHUZHUMMLU-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 855.01 | Molecular Weight (Monoisotopic): 854.4228 | AlogP: 3.60 | #Rotatable Bonds: 11 |
Polar Surface Area: 181.01 | Molecular Species: BASE | HBA: 14 | HBD: 3 |
#RO5 Violations: 2 | HBA (Lipinski): 16 | HBD (Lipinski): 4 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: 8.45 | CX Basic pKa: 8.84 | CX LogP: 2.99 | CX LogD: 2.49 |
Aromatic Rings: 4 | Heavy Atoms: 63 | QED Weighted: 0.19 | Np Likeness Score: -0.77 |
1. Sabnis RW.. (2022) Bifunctional Compounds as SMARCA2 Degraders for Treating Cancer., 13 (1.0): [PMID:35059115] [10.1021/acsmedchemlett.1c00657] |
Source(1):